A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Wugen, Inc.
Ohio State University Comprehensive Cancer Center
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
The First Affiliated Hospital of Soochow University
Thomas Jefferson University
National Cancer Institute (NCI)
Celgene